Register or Sign in to Save this opportunity, or Send an Inquiry.
Buprenorphine TDS
Amarin Technologies S.A. Argentina flag Argentina
Abstract ID:
Transdermal system for the treatment of moderate to severe pain that do not adequately respond to non-opioid analgesics.
Send an Inquiry
RE:
Participants
You

Buprenorphine patch is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Amarin has developed a 7-day Buprenorphine TDS using its drug-in-adhesive technology, and has completed a Phase I PK comparative with the original product.

Results indicated that our patch would be bioequivalent to BuTrans®/Norspan® with a lesser size and lower drug content than the RLD. Adhesion and dermal response were similar to the RLD.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
AMARIN patch has been licensed for the US market. AMARIN is seeking to license this product for Europe and RoW.
FEATURED
Last Updated Dec 2017
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION

Opportunity Contact